Key clinical point: Daily lenvatinib plus weekly paclitaxel was considered active and well tolerated in a phase 1 trial of patients with recurrent endometrial or ovarian cancer.
Major finding: The combination produced an objective response rate of 65%, and most adverse events were grade 1 or 2.
Study details: Phase 1 trial of 26 patients.
Disclosures: This investigator-initiated study was supported by Eisai. The speaker disclosed relationships with Eisai, ImmunoGen, Clovis Oncology, Tesaro, Merck, and Agenus.
Backes FJ et al. SGO 2019, Abstract LBA5.